Your browser doesn't support javascript.
loading
Paclitaxel and gemcitabine combinational drug-loaded mucoadhesive delivery system in the treatment of colon cancers.
Guo, X-Y; Wang, P; Du, Q-G; Han, S; Zhu, S-M; Lv, Y-F; Liu, G-S; Hao, Z-M.
  • Guo XY; Department of Gastroenterology, The Third Affiliated Hospital, College of Medicine, Xi'an Jiaotong University, Xi'an, China.
  • Wang P; Department of Gastroenterology, The Third Affiliated Hospital, College of Medicine, Xi'an Jiaotong University, Xi'an, China.
  • Du QG; Department of General Surgery, The Third Affiliated Hospital, College of Medicine, Xi'an Jiaotong University, Xi'an, China.
  • Han S; State Key Laboratory of Cancer Biology & Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China.
  • Zhu SM; Department of Gastroenterology, The Third Affiliated Hospital, College of Medicine, Xi'an Jiaotong University, Xi'an, China.
  • Lv YF; Department of Gastroenterology, The Third Affiliated Hospital, College of Medicine, Xi'an Jiaotong University, Xi'an, China.
  • Liu GS; Department of Gastroenterology, The Third Affiliated Hospital, College of Medicine, Xi'an Jiaotong University, Xi'an, China.
  • Hao ZM; Department of Gastroenterology, The First Affiliated Hospital, College of Medicine, Xi'an Jiaotong University, Xi'an, China.
Drug Res (Stuttg) ; 65(4): 199-204, 2015 Apr.
Article en En | MEDLINE | ID: mdl-24941086
The combination of two different types of chemo-therapeutic drugs via nanocarriers is emerged as a promising strategy for treating multiple cancers. Such a co-delivery system will synchronize the drug exposure and synergize the therapeutic effects. Herein, we prepared a paclitaxel (PTX) and gemcitabine (GEM)-loaded N-succinyl chitosan nanoparticles (NSC NP) to target colon cancer. NSC NP showed a pH sensitive swelling at colonic pH and exhibited a sequential release pattern for both the drugs. Binary drug combination exhibited a synergistic cytotoxicity against HT-29 colon cancer cells with a remarkable G2/M phase arrest. Specifically, in vivo antitumor efficacy study showed that NSC NP prolonged the survival time of tumor-bearing mice up to 45 days wherein 50% of mice were still alive. Therefore, these results suggest that co-delivery of drugs with a suitable delivery system could potentially improve the therapeutic efficacy in colon cancers. The study can be further continued by using different types of chemotherapeutic drugs that targets different molecular targets using pH-sensitive nanocarriers.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Portadores de Fármacos / Paclitaxel / Neoplasias del Colon / Desoxicitidina / Nanopartículas Límite: Animals / Humans Idioma: En Año: 2015 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Portadores de Fármacos / Paclitaxel / Neoplasias del Colon / Desoxicitidina / Nanopartículas Límite: Animals / Humans Idioma: En Año: 2015 Tipo del documento: Article